BDBM610681 5-[(2R,6S)-2-methyl-6-[[4-[(7S)-7-methyl-5,6,7,8-tetrahydro-2,6-naphthyridin-3-yl]piperazin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile and 5-[(2R,6S)-2-methyl-6-[[4-[(7R)-7-methyl-5,6,7,8-tetrahydro-2,6-naphthyridin-3-yl]piperazin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile::US11713327, Example 76

SMILES C[C@H]1Cc2cnc(cc2CN1)N1CCN(C[C@H]2CN(C[C@@H](C)O2)c2ccc(C#N)c3ncccc23)CC1

InChI Key InChIKey=KOACSZUGTWKSAL-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 610681   

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM610681(US11713327, Example 76 | 5-[(2R,6S)-2-methyl-6-[[4...)
Affinity DataIC50: 2.00E+4nMAssay Description:The hERG channel inhibition assay is a highly sensitive measurement that identifies compounds exhibiting hERG inhibition related to cardiotoxicity in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent